Vivoryon shares fall below €0.78 and hit a two-year low
The stock of the biotech company specialised in kidney diseases drops sharply intraday as it publishes its accounts for the first nine months. The release shows a reduction in losses, but also very tight cash.
A stock below all its moving averages, at its lowest in two years
Vivoryon shares fall 27.03% to €0.66, after an intraday low at €0.65, erasing the previous record decline of €0.76 set in 2024.
During the session, the stock broke through its €0.78 threshold, which has now become resistance, and remains below it. This sell-off follows a drop of nearly 40% over three months, while the share price sits well below its 20-day moving average (a gap of 25.4%).
The RSI at 25 indicates a marked oversold condition. Meanwhile, major European indices are trading in positive territory, with the CAC 40 gaining 0.55% intraday.
Accounts show a €4.8M loss, but cash reduced to €1.7M
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In its accounts published this morning, Vivoryon reports a net loss of €4.8M over nine months, compared with €7.6M a year earlier, thanks to lower expenses. Cash, meanwhile, fell to €1.7M as of September 30, versus €5.6M at the end of 2025.
According to the group, its resources cover its needs until the second half of December 2026, and it states that its ability to continue operating depends on obtaining additional financing.
The company is negotiating a partnership or financing for varoglutamstat and is exploring other options, including a sale of the company or of its assets. The launch of the Phase 2b study in diabetic nephropathy remains contingent on this financing.
Related
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Net income: -4,8 millions d'euros
Guidance from the release
« The Company has concluded that the ability to continue as a going concern, depends on the ability to generate additional funding. » ; « its existing cash and cash equivalents will now be sufficient to fund its operating plans into the second half of December 2026 »
Risks mentioned
Company's viability beyond second half of December 2026 is dependent on ability to raise additional funds
Phase 2b DKD study initiation is subject to additional funding and partnership completion
Continued operating losses expected; business dependent on success of ongoing R&D activities
Opportunities identified
Varoglutamstat Phase 2 program has shown statistically significant kidney function improvement in two independent studies
Active negotiations with multiple parties regarding partnership or financing for varoglutamstat development
New computational analysis provides additional mechanistic support for QPCT/L inhibition in kidney disease
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
